ChronoScale Holdings Corp(CHRN)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $18.3M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
CHRN Stock Analysis & AI Quality Score
AI stock analysis and institutional research for ChronoScale Holdings Corp (CHRN), a Industrials sector company. CHRN is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $18.3m in revenue. Based on the latest XBRL financial filings (Q1 2026), ChronoScale Holdings Corp reports quarterly revenue of $2.1M, net income of $-6.9M, free cash flow of $-2.1M. CHRN trades on the Nasdaq exchange and files with the SEC under CIK 1549084. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CHRN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ChronoScale Holdings Corp directly from SEC EDGAR.
Revenue
Q1 2026
$2.1M
Net Income
Q1 2026
$-6.9M
Free Cash Flow
Q1 2026
$-2.1M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
-1.9% YoYNet Income
+25.5% YoYOperating Income
+30.8% YoYEPS (Diluted)
-666.4% YoYTotal Assets
-7.8% YoYTotal Debt
Op. Cash Flow
+18.3% YoY| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2018 |
|---|---|---|---|---|---|---|
| Revenue | $17.9M -1.9% | $18.3M +41.6% | $12.9M +14.8% | $11.2M +26.6% | $8.9M -21.6% | $11.3M |
| Net Income | $-11.3M +25.5% | $-15.2M -0.8% | $-15.1M -54.4% | $-9.8M +38.3% | $-15.8M +41.4% | $-27.0M |
| Operating Income | $-10.5M +30.8% | $-15.1M +2.9% | $-15.6M -12.5% | $-13.8M -4.0% | $-13.3M +50.8% | $-27.0M |
| EPS (Diluted) | $-8.43 -666.4% | $-1.10 +5.2% | $-1.16 -31.8% | $-0.88 +60.2% | $-2.21 -402.3% | $-0.44 |
| Total Assets | $26.7M -7.8% | $28.9M -29.3% | $40.9M -16.8% | $49.2M +138.7% | $20.6M +16.7% | $17.7M |
| Total Debt | — | — | — | $2.0M +0.2% | $2.0M -72.8% | $7.3M |
| Operating Cash Flow | $-9.8M +18.3% | $-12.1M +17.9% | $-14.7M -31.7% | $-11.2M -27.4% | $-8.8M +60.5% | $-22.2M |
AI Insight: CHRN Financial Trends
Equity collapsed from $13M to $2M in just two quarters as losses accelerated sharply in Q4 2025 and Q1 2026.
• Revenue deteriorated from $5M in Q2 2024 to $2M in Q1 2026, with no quarter showing recovery above $5M.
• Operating loss widened dramatically to -$6M in Q1 2026 from -$2M in Q2 2024, the worst level in the dataset.
• Equity eroded from $15M peak in Q3 2024 to just $2M in Q1 2026, an $13M decline over five quarters.
⚠ Equity of $2M in Q1 2026 is near zero; another quarter of -$7M net loss would render the company technically insolvent.
⚠ Operating cash outflow of -$4M in Q4 2025 signals accelerating cash burn — liquidity runway is critically short.
⚠ No debt reported across all periods; any new debt issuance to fund operations would signal deepening financial stress.
AI Insight: CHRN Ratio Trends
EKSO Bionics remains deeply unprofitable with operating margins swinging wildly between -33% and -193% across recent quarters, offering no clear path to profitability.
• Operating margin has been consistently negative, ranging from -33.2% in Q3 2025 to -193.2% in Q2 2025, with no sustained improvement.
• ROA deteriorated sharply to -93.0% in Q4 2025 from -26.2% in Q3 2025, signaling worsening asset efficiency quarter-over-quarter.
• ROIC data is frequently unavailable (gaps in Q1 2025, Q2 2025, Q4 2025, Q1 2026), limiting visibility into capital return trends.
⚠ TTM operating margin of -134.1% and NPM of -135.7% reflect severe cash burn — sustainability of operations is a key concern.
⚠ Q3 2025 showed a relative improvement to -33.2% operating margin, but Q4 2025 reversed sharply to -143.6% — watch for pattern persistence.
⚠ D/E is absent across all periods; debt structure is opaque and warrants scrutiny given persistent losses and negative equity implied by missing ROE.
Get alerted when CHRN's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for ChronoScale Holdings Corp including:
Top Institutional Holders of CHRN
RESOURCES MANAGEMENT CORP /CT/ /ADV
$7.00666 sh
| Fund | Value | Shares |
|---|---|---|
| RESOURCES MANAGEMENT CORP /CT/ /ADV | $7.00 | 666 |
More Industrials Companies
View all Industrials →Put CHRN on your watchlist
Track score changes the day ChronoScale Holdings Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CHRN a good stock to buy?
13F Pro's AI-powered analysis of ChronoScale Holdings Corp (CHRN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Industrials sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CHRN are available on the CHRN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own CHRN?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CHRN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ChronoScale Holdings Corp's investment landscape.